Jochen Imig

Dr. Jochen Imig


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in Cancer Cell
Verified
Journal Article
Closed access
EWEric Wang
Eric Wang
SLSydney X. Lu
Sydney X. Lu
APAlessandro Pastore
Alessandro Pastore
XCXufeng Chen
Xufeng Chen
JIJochen Imig
Jochen Imig
IAIannis Aifantis
Iannis Aifantis

1 January 2020 in Cancer Cell
Verified
Journal Article
Closed access
DHDouglas Hanniford
Douglas Hanniford
AUAlejandro Ulloa-Morales
Alejandro Ulloa-Morales
AKAlcida Karz
Alcida Karz
MBMaria Gabriela Berzoti-Coelho
Maria Gabriela Berzoti-Coelho
RMRana S. Moubarak
Rana S. Moubarak
EHEva Hernando
Eva Hernando

22 December 2014 in Nature Chemical Biology
Verified
Journal Article
Closed access
JIJochen Imig
Jochen Imig
ABAndreas Brunschweiger
Andreas Brunschweiger
ABAnneke Brümmer
Anneke Brümmer
BGBoris Guennewig
Boris Guennewig
NMNitish Mittal
Nitish Mittal
JHJonathan Hall
Jonathan Hall

9 June 2011 in Blood
Verified
Journal Article
Open access
PDF file
VCVanessa J. Craig
Vanessa J. Craig
SCSergio B. Cogliatti
Sergio B. Cogliatti
JIJochen Imig
Jochen Imig
CRChristoph Renner
Christoph Renner
SNStefan Neuenschwander
Stefan Neuenschwander
AMAnne Müller
Anne Müller
Gastric marginal zone B-cell lymphoma of MALT type (MALT lymphoma) arises in the context of chronic inflammation induced by the bacterial pathogen Helicobacter pylori. Although generally considered an indolent disease, MALT lymphoma may transform to gastric diffuse large B-cell lymphoma (gDLBCL) through mechanisms that remain poorly understood. By comparing microRNA expression profiles of gastric MALT lymphoma and gDLBCL, we have identified a signature of 27 deregulated microRNAs(miRNAs) that share the characteristic of being transcriptionally repressed by Myc. Myc overexpression was consequently detected in 80% of gDLBCL but only 20% of MALT lymphomas spotted on a tissue microarray. A highly similar signature of Myc-repressed miRNAs was further detected in nodal DLBCL. Small interfering RNA–mediated knock-down of Myc blocked proliferation of DLBCL cell lines. Of the Myc-repressed miRNAs down-regulated in malignant lymphoma, miR-34a showed the strongest antiproliferative properties when overexpressed in DLBCL cells. We could further attribute miR-34a's tumor-suppressive effects to deregulation of its target FoxP1. FoxP1 overexpression was detected in gDLBCL but not in gastric MALT lymphoma; FoxP1 knock-down efficiently blocked DLBCL proliferation. In conclusion, our results elucidate a novel Myc- and FoxP1-dependent pathway of malignant transformation and suggest miR-34a replacement therapy as a promising strategy in lymphoma treatment.

8 November 2010 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
JIJochen Imig
Jochen Imig
NMNatalie Motsch
Natalie Motsch
JZJia Yun Zhu
Jia Yun Zhu
SBStephanie Barth
Stephanie Barth
MOMichal Okoniewski
Michal Okoniewski
FGFriedrich Grässer
Friedrich Grässer
The Epstein–Barr virus (EBV) is an oncogenic human Herpes virus found in ∼15% of diffuse large B-cell lymphoma (DLBCL). EBV encodes miRNAs and induces changes in the cellular miRNA profile of infected cells. MiRNAs are small, non-coding RNAs of ∼19–26 nt which suppress protein synthesis by inducing translational arrest or mRNA degradation. Here, we report a comprehensive miRNA-profiling study and show that hsa-miR-424, -223, -199a-3p, -199a-5p, -27b, -378, -26b, -23a, -23b were upregulated and hsa-miR-155, -20b, -221, -151-3p, -222, -29b/c, -106a were downregulated more than 2-fold due to EBV-infection of DLBCL. All known EBV miRNAs with the exception of the BHRF1 cluster as well as EBV-miR-BART15 and -20 were present. A computational analysis indicated potential targets such as c-MYB, LATS2, c-SKI and SIAH1. We show that c-MYB is targeted by miR-155 and miR-424, that the tumor suppressor SIAH1 is targeted by miR-424, and that c-SKI is potentially regulated by miR-155. Downregulation of SIAH1 protein in DLBCL was demonstrated by immunohistochemistry. The inhibition of SIAH1 is in line with the notion that EBV impedes various pro-apoptotic pathways during tumorigenesis. The down-modulation of the oncogenic c-MYB protein, although counter-intuitive, might be explained by its tight regulation in developmental processes.

1 December 2005 in Molecular Biology of the Cell
Verified
Journal Article
Closed access
SKSimone Kiermayer
Simone Kiermayer
RBRicardo M. Biondi
Ricardo M. Biondi
JIJochen Imig
Jochen Imig
GPGuido Plotz
Guido Plotz
JHJörg Haupenthal
Jörg Haupenthal
APAlbrecht Piiper
Albrecht Piiper
Elevation of the intracellular cAMP concentration ([cAMP]i) regulates metabolism, cell proliferation, and differentiation and plays roles in memory formation and neoplastic growth. cAMP mediates its effects mainly through activation of protein kinase A (PKA) as well as Epac1 and Epac2, exchange factors activating the small GTPases Rap1 and Rap2. However, how cAMP utilizes these effectors to induce distinct biological responses is unknown. We here studied the specific roles of PKA and Epac in neuroendocrine PC12 cells. In these cells, elevation of [cAMP]iactivates extracellular signal-regulated kinase (ERK) 1/2 and induces low-degree neurite outgrowth. The present study showed that specific stimulation of PKA triggered ERK1/2 activation that was considerably more transient than that observed upon simultaneous activation of both PKA and Epac. Unexpectedly, the PKA-specific cAMP analog induced cell proliferation rather than neurite outgrowth. The proliferative signaling pathway activated by the PKA-specific cAMP analog involved activation of the epidermal growth factor receptor and ERK1/2. Activation of Epac appeared to extend the duration of PKA-dependent ERK1/2 activation and converted cAMP from a proliferative into an anti-proliferative, neurite outgrowth-promoting signal. Thus, the present study showed that the outcome of cAMP signaling can depend heavily on the set of cAMP effectors activated.